Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors-Reference-Cited by-同舟云学术

Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors

Published:2019-02-21 Issue:3 Volume:10 Page:383-388
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Liu Chunjian¹^ORCID,Lin James¹,Moslin Ryan¹,Tokarski John S.¹,Muckelbauer Jodi¹,Chang ChiehYing¹,Tredup Jeffrey¹,Xie Dianlin¹,Park Hyunsoo¹,Li Peng¹,Wu Dauh-Rurng¹,Strnad Joann¹,Zupa-Fernandez Adriana¹,Cheng Lihong¹,Chaudhry Charu¹,Chen Jing¹,Chen Cliff¹,Sun Huadong¹,Elzinga Paul¹,D’arienzo Celia¹,Gillooly Kathleen¹,Taylor Tracy L.¹,McIntyre Kim W.¹,Salter-Cid Luisa¹,Lombardo Louis J.¹,Carter Percy H.¹^ORCID,Aranibar Nelly¹,Burke James R.¹,Weinstein David S.¹

Affiliation:

1. Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.9b00035

Reference28 articles.

1. A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors

2. Janus kinases in immune cell signaling

3. Regulation of JAK–STAT signalling in the immune system